

# Injection Site Reactions with Subcutaneous Lenacapavir Administration at Alternate Injection Sites

Gary Saunders<sup>1\*</sup>, Eva Mortensen<sup>2</sup>, Gong Shen<sup>2</sup>, Aryun Kim<sup>2</sup>

<sup>1</sup>Gilead Sciences, Inc., Cambridge, United Kingdom; <sup>2</sup>Gilead Sciences, Inc., Foster City, California, United States

\*Presenting author

Copies of this poster obtained through QR (Quick Response) and/or text key codes are for personal use only and may not be reproduced without written permission of the authors.



## Conclusions

- The frequency of injection site reactions (ISRs) at alternate injection sites following subcutaneous (SC) lenacapavir (LEN) administration was generally similar when compared with the abdomen as reference
- ISRs were predominantly Grade 1/2, with only one Grade 3
- Safety data reported here, together with previously reported pharmacokinetic (PK) data, support further investigation of alternate injection sites for SC LEN administration
- More data on ISRs at alternate injection sites will be collected in future studies of LEN for pre-exposure prophylaxis

## Plain Language Summary

- Lenacapavir is a medicine approved for the treatment of HIV infection in people who have already received many different HIV medicines but whose current medicines are not working
- Lenacapavir is usually given as an injection under the skin in the stomach area once every six months
  - Side effects can occur where the injection is given, including pain, redness, swelling, lumps under and thickening of the skin
  - Giving the injections in different locations of the body could help make these side effects less bothersome
- In this study, people without HIV were given lenacapavir injections in one of four different locations of the body: thigh, upper arm, buttocks, or stomach area
  - We assessed the number and type of side effects between the different injection sites
- Overall, no one experienced any serious side effects
  - Side effects were mostly mild-to-moderate, whether the injection was given in the thigh, upper arm, buttocks, or stomach area

## Background

- LEN is a first-in-class, long-acting, HIV-1 capsid inhibitor approved for the treatment of multidrug-resistant HIV-1 infection, in combination with other antiretrovirals, in heavily treatment-experienced individuals<sup>1,2</sup>
- Following oral loading doses, LEN is administered as SC injections (927 mg given as 2 x 1.5 mL injections) in the abdomen every 6 months<sup>1,2</sup>
- ISRs are the most commonly reported adverse event (AE) following SC LEN administration
  - Rotation of SC LEN injections between different anatomical sites could mitigate the impact of ISRs and facilitate long-term adherence
- We conducted a Phase 1 study in participants without HIV-1 to evaluate the PK and safety of SC LEN administration at alternate injection sites using the abdomen as a reference
  - PK data were previously reported; LEN SC injection in the thigh, upper arm, and gluteal region achieved similar or slightly higher overall LEN exposures compared with the reference abdomen injection<sup>3</sup>

## Objective

- To evaluate the safety of a single dose of SC LEN injection into the thigh, upper arm, and gluteal region compared with the abdomen

## Methods

- This was a Phase 1, open-label, parallel design, randomized, single-dose study
- Participants were healthy males and nonpregnant, nonlactating females aged 18–55 years old with a body mass index of 19–30 kg/m<sup>2</sup>
- Participants received a single dose of SC LEN (927 mg as two 1.5 mL injections) bilaterally, either in the thigh, upper arm, or gluteal region or in different quadrants of the abdomen
- Safety endpoints were incidence of AEs and laboratory abnormalities
- Injection site examinations were performed on Day 1, daily on Days 2–10, and at each subsequent visit through Day 270

## Results

- Baseline characteristics were generally balanced between cohorts (Table 1)
  - Overall median age was 46 years, and 50% of participants were male


Table 1. Baseline Characteristics

	Thigh n=10	Upper arm n=10	Gluteal region n=10	Abdomen n=10
Median (IQR) age, years	48 (39–51)	43 (38–47)	44 (31–48)	49 (36–51)
Male, n (%)	5 (50)	6 (60)	4 (40)	5 (50)
Race, n (%)				
White	7 (70)	8 (80)	10 (100)	7 (70)
Black or African American	3 (30)	2 (20)	0	3 (30)
Mean (SD) BMI, kg/m <sup>2</sup>	27.0 (1.6)	27.2 (2.9)	26.9 (2.2)	27.0 (2.4)

BMI, body mass index

- Of the 40 participants enrolled, four discontinued the study: one due to a protocol violation (abdomen cohort), one due to consent withdrawal (gluteal region cohort), and two who were lost to follow-up (thigh cohort, abdomen cohort)
- There were no serious AEs, and no AEs led to study discontinuation
- Treatment-related AEs occurred in 38/40 (95%) participants
  - Except for ISRs, all treatment-related AEs were Grade 1
- ISRs occurred in 38/40 (95%) participants
  - Most ISRs were Grade 1 or 2; one Grade 3 (erythema, upper arm cohort) was observed (Figure 1)
  - The most common ISRs were pain (90% of participants), induration (73%), erythema (70%), nodules (15%), and swelling (15%); incidence across injection site cohorts is shown in Figure 1

Figure 1. Most Common ISRs by Injection Site



All cohorts n=10 each  
ISR, injection site reaction

## References:

1. Lenacapavir Prescribing Information. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/215973s0001bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215973s0001bl.pdf) (Accessed June 2024).
2. Lenacapavir Summary of Product Characteristics. Available at: [https://www.ema.europa.eu/en/documents/product-information/sunlenca-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/sunlenca-epar-product-information_en.pdf) (Accessed June 2024).
3. Lat A, et al., Poster #1542, Presented at IDWeek 2023, October 11–15, Boston, Massachusetts, USA.

## Acknowledgments:

This study was funded by Gilead Sciences, Inc. Medical writing support was provided by Gabriella Greenwood, BSc, of Ashfield MedComms (Macclesfield UK), an Inizio company, and was funded by Gilead Sciences, Inc.

## Disclosures:

AK, EM, GS, and GS are all employees and shareholders of Gilead Sciences, Inc.